Lenalidomide: From bench to bedside (part 1)

Cancer Control

Volumn 13, Issue SUPPL., 2006, Pages 2-3

  List, Alan F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; LENALIDOMIDE;

DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; ERYTHROCYTE TRANSFUSION; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33846425712     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601304s01     Document Type: Editorial

References (2)

1. List AF, Sandberg AA, Doll DC. Myelodysplastic syndromes. In: Wintrobe's Clinical Hematology. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004:2207-2234.
2. Celgene Corp. Revlimid® package insert. Summit, NJ; July 2006.